ID | 1361 |
Name of the vaccine | Minhai-HIB |
Microbe | Bacteria |
Disease name | Haemophilus influenzae type b (Hib) |
Name of bacteria | Haemophilus influenzae |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 2 to 5 years |
Description of the vaccine | Haemophilus Influenzae type b conjugate vaccine, freeze-dried. |
Name of the manufacturer | Beijing Minhai Biotechnology Co., Ltd |
Name of the manufacturing country | China |
Year of manufacture | 2016 |
Clinical Phase status | Clinical - Phase 3 |
Bacterial strain | Anaerobic gram-negative coccobacillus. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Children 1 to 5 years: Single dose.
Children 6 to 11 months: Two doses, 1 month apart.
Infants 2 to 5 months: Three doses, 1 month apart. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Both |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT02560272 |
Reference | NA |
Other name | NA |
Additional Links | NA
|